Detalhe da pesquisa
1.
Drug-repositioning screening identified fludarabine and risedronic acid as potential therapeutic compounds for malignant pleural mesothelioma.
Invest New Drugs
; 39(3): 644-657, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33300108
2.
DNA repair and cancer in colon and rectum: Novel players in genetic susceptibility.
Int J Cancer
; 146(2): 363-372, 2020 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31209889
3.
Mesothelin promoter variants are associated with increased soluble mesothelin-related peptide levels in asbestos-exposed individuals.
Occup Environ Med
; 74(6): 456-463, 2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28343162
4.
Topoisomerase 1 Promoter Variants and Benefit from Irinotecan in Metastatic Colorectal Cancer Patients.
Oncology
; 91(5): 283-288, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27577551
5.
Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer.
BMC Cancer
; 15: 874, 2015 Nov 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-26553291
6.
Epigenetics and chemoresistance in colorectal cancer: an opportunity for treatment tailoring and novel therapeutic strategies.
Drug Resist Updat
; 14(6): 280-96, 2011 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-21955833
7.
Targeting hypoxic response for cancer therapy.
Oncotarget
; 7(12): 13464-78, 2016 Mar 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-26859576
8.
Novel genetic variants in differentiated thyroid cancer and assessment of the cumulative risk.
Sci Rep
; 5: 8922, 2015 Mar 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-25753578
9.
A polymorphism in the promoter is associated with EZH2 expression but not with outcome in advanced pancreatic cancer patients.
Pharmacogenomics
; 15(5): 609-18, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24798718
10.
Novel genome-wide association study-based candidate loci for differentiated thyroid cancer risk.
J Clin Endocrinol Metab
; 99(10): E2084-92, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25029422
11.
Histone lysine demethylases in breast cancer.
Crit Rev Oncol Hematol
; 86(2): 97-103, 2013 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-23266085
12.
A single nucleotide polymorphism in EZH2 predicts overall survival rate in patients with cholangiocarcinoma.
Oncol Lett
; 6(5): 1487-1491, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-24179546
13.
Polycomb genes and cancer: time for clinical application?
Crit Rev Oncol Hematol
; 83(2): 184-93, 2012 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-22112692
14.
An aromatase polymorphism (g.132810C>T) predicts risk of bisphosphonate-related osteonecrosis of the jaw.
Biomark Med
; 6(2): 201-9, 2012 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-22448795
15.
Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells.
Mol Cancer Ther
; 11(8): 1735-46, 2012 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-22622284